Abstract Number: 1294 • ACR Convergence 2025
Implementation of Pneumococcal Vaccination in Patients with Childhood-Onset Systemic Lupus Erythematous
Background/Purpose: Pneumococcal vaccination is critical in patients with childhood-onset systemic lupus erythematosus (cSLE) due to their immunocompromised status and increased susceptibility to serious infections. Despite…Abstract Number: 1278 • ACR Convergence 2025
Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus
Background/Purpose: Patient and provider discordance can negatively impact medication adherence and disease outcomes in pediatric lupus. Functional status is known to greatly affect perception of…Abstract Number: 0428 • ACR Convergence 2025
The OMERACT Juvenile Idiopathic Arthritis MRI Score for Active and Structural Lesions in the Sacroiliac Joints: Development and Validation in Two Longitudinal Cohorts
Background/Purpose: The OMERACT Juvenile Idiopathic Arthritis MRI (JAMRIS) Working group has defined a spectrum of MRI lesions in the sacroiliac joint (SIJ) in youth with…Abstract Number: 0402 • ACR Convergence 2025
Risk Factors for Anti-Adalimumab Antibody Development in Pediatric Patients Using Adalimumab for Rheumatic Disease and Associated Conditions
Background/Purpose: Adalimumab is a monoclonal antibody against TNF-α that is commonly used to treat JIA, hidradenitis suppurativa (HS), chronic uveitis, sarcoidosis, and chronic nonbacterial osteomyelitis…Abstract Number: 0126 • ACR Convergence 2025
Performance of the 2023 and 2006 APS Classification Criteria in Pediatric Patients Diagnosed with APS: A Multisite Cohort Study
Background/Purpose: Antiphospholipid syndrome (APS) is a thrombo-inflammatory disorder that causes significant morbidity and mortality, even in children. The 2023 ACR/EULAR classification criteria, which use weighted…Abstract Number: 2537 • ACR Convergence 2025
Variation in Treatment Approaches in IgA-Vasculitis Among Pediatricians and Pediatric rheumatologists: A Cross-Sectional International Survey
Background/Purpose: IgA Vasculitis (IgAV) is the most common small-vessel vasculitis in children. Although there is no evidence-based recommendations for treating IgAV, the European SHARE recommendations…Abstract Number: 2154 • ACR Convergence 2025
Whole-Body MRI Findings in a Cohort of Children with Chronic Nonbacterial Osteomyelitis
Background/Purpose: Chronic nonbacterial osteomyelitis (CNO) is an autoinflammatory bone disorder characterized by multifocal, sterile bone inflammation in childhood. Whole-body magnetic resonance imaging (WB-MRI) allows for…Abstract Number: 2130 • ACR Convergence 2025
Systemic juvenile idiopathic arthritis- Fifteen-year experience from a tertiary centre at Bristol, United Kingdom
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) is a chronic disease that results in significant morbidity and mortality in children1. Improved understanding of the pathophysiology of…Abstract Number: 1815 • ACR Convergence 2025
New-Onset Juvenile Spondyloarthritis is Characterized by Bone Metabolism Disturbances with Biomarker Potential
Background/Purpose: Juvenile spondyloarthritis (JSpA) management is hindered by the lack of reliable biomarkers to predict which patients will develop progressive structural changes, such as erosions…Abstract Number: 1672 • ACR Convergence 2025
Classification criteria, disease phenotypes and long-term outcomes of childhood Sjögren’s Disease into adulthood
Background/Purpose: Childhood Sjögren Disease (cSjD) is a rare clinical phenotype lacking research on long-term outcomes and impact on the quality of life of young people…Abstract Number: 1293 • ACR Convergence 2025
Synovitis and periarticular soft tissues abnormalities in childhood-onset systemic lupus erythematosus: an ultrasonography study
Background/Purpose: Musculoskeletal (MSK) involvement occurs in up to 70% of childhood-onset systemic lupus erythematosus (cSLE). MSK ultrasound (US) has emerged as a tool with greater…Abstract Number: 1277 • ACR Convergence 2025
Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease
Background/Purpose: Current practice guidelines recommend either rituximab (RTX) or cyclophosphamide (CYC) for treatment of organ-threatening manifestations of systemic vasculitis or connective tissue disease (e.g., diffuse…Abstract Number: 0427 • ACR Convergence 2025
Maternal Smoking During Pregnancy and Risk of Juvenile Idiopathic Arthritis (JIA): Triangulating Evidence from Polygenic Risk Scores and Meta-Analysis in Scandinavian Birth Cohorts
Background/Purpose: Maternal smoking during pregnancy has been associated with a seemingly lower risk of juvenile idiopathic arthritis (JIA) in the child (1), contrasting with smoking’s…Abstract Number: 0401 • ACR Convergence 2025
Longitudinal Effectiveness of Abatacept in JIA: Results From an Ongoing JIA Registry
Background/Purpose: Abatacept is a selective T-cell co-stimulation modulator approved for use in JIA. Efficacy and safety of abatacept in patients (pts) with JIA have been…Abstract Number: 0119 • ACR Convergence 2025
Thrombin Generation Assays Inform Hypercoagulability Mediated by Antiphospholipid Antibodies in Children with Systemic Lupus Erythematosus
Background/Purpose: In pediatric systemic lupus erythematosus (SLE), antiphospholipid antibodies (aPL) are independent risk factors for thrombosis. However, data are limited on how aPL impact hypercoagulability.…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 62
- Next Page »
